MAPT and amyloidosis: According to the new Revised Criteria, p‐tau217 has been proposed as a T1 biomarker, representative of soluble tau fragments that may reflect a reaction to amyloid plaques or to soluble Aβ species in plaque penumbra, and so a very first stage of phosphorylation and secretion of tau induced by amyloid pathology.2